Title
Drug-resistance mechanisms and tuberculosis drugs
Date Issued
24 January 2015
Access level
open access
Resource Type
journal article
Author(s)
Köser C.U.
Javid B.
Liddell K.
Ellington M.J.
Feuerriegel S.
Niemann S.
Brown N.M.
Burman W.J.
Abubakar I.
Ismail N.A.
Peacock S.J.
Török M.E.
London School of Hygiene and Tropical Medicine
Publisher(s)
Lancet Publishing Group
Start page
305
End page
307
Volume
385
Issue
9965
Language
English
OCDE Knowledge area
Enfermedades infecciosas
Farmacología, Farmacia
Scopus EID
2-s2.0-84921520920
PubMed ID
Source
The Lancet
ISSN of the container
01406736
Sponsor(s)
This publication presents independent research supported by the Health Innovation Challenge Fund (HICF-T5-342 and WT098600), a parallel funding partnership between the UK Department of Health and Wellcome Trust. The views expressed in this publication are those of the authors and not necessarily those of the Department of Health, Public Health England, or the Wellcome Trust. CUK received travel expenses to a scientific meeting from Janssen. CUK, SN, and SJP are collaborating with the TB Alliance and Otsuka Pharmaceutical to test the in-vitro potency of delamanid, PA-824, and TBA-354. BJ is a Tsinghua-Janssen Scholar. MJE was funded by Bruker Daltonics to attend a conference. NMB is a consultant for Discuva Ltd, was funded by Astellas Pharma Ltd to attend a conference, and is the President of the British Society for Antimicrobial Chemotherapy. WJB chairs the Data and Safety Monitoring Boards for clinical trials of bedaquiline. SJP has received funding for travel and accommodation from Illumina Inc. MET was funded by Illumina Inc to attend a conference. KL, IA, NAI, and KL declare no competing interests.
Sources of information:
Directorio de Producción Científica
Scopus